8-K 1 b48813ace8vk.txt ALKERMES CLINICAL PARTNERS, L.P. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT -- DECEMBER 9, 2003 (Date of earliest event reported) ALKERMES CLINICAL PARTNERS, L.P. (Exact name of Registrant as specified in its charter) DELAWARE 0-26758 043-145043 (State of organization) (Commission file number) (IRS employer identification number) 88 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS 02139 (Address of principal executive offices, zip code) AREA CODE (617) 494-0171 (Telephone number) ITEM 5. OTHER EVENTS. ------------ The Limited Partners of Alkermes Clinical Partners, L.P. met on December 9, 2003 and voted to adjourn the scheduled Special Meeting of Limited Partners until 10:00 a.m., local time, on December 17, 2003. The Special Meeting will reconvene at the offices of Alkermes, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139 for the following purposes: 1. To consider and vote upon a proposal to terminate Alkermes Clinical Partners, L.P. pursuant to Section 9.1 of the Alkermes Clinical Partners, L.P. Agreement of Limited Partnership, dated February 7, 1992, as amended, among Alkermes Development Corporation, II, a Delaware corporation, the Initial Limited Partner and Additional Limited Partners. 2. To transact such other business as may properly come before the meeting. Only holders of record of Alkermes Clinical Partners, L.P. limited partnership interests at the close of business on October 2, 2003 are entitled to vote at the adjourned special meeting or any subsequent adjournments or postponements thereof. Approval of the termination proposal at the special meeting requires the favorable vote of the holders of at least two-thirds in interest of the Limited Partners in person or by proxy. SIGNATURES ---------- Pursuant to requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 15, 2003 Alkermes Clinical Partners, L.P. By: /s/ James M. Frates ---------------------------------------- James M. Frates Chief Financial Officer, Vice President, Treasurer and Assistant Secretary